<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131150">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01939977</url>
  </required_header>
  <id_info>
    <org_study_id>ACA-SPAI-11-24</org_study_id>
    <secondary_id>2013-001326-25</secondary_id>
    <nct_id>NCT01939977</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.</brief_title>
  <acronym>PARIDOINAL2013</acronym>
  <official_title>Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Renal Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Senefro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Effice Servicios Para la Investigacion S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Senefro</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the superiority of paricalcitol treatment at
      early renal post-transplantation (M6) in the control of iPTH (Intact parathyroid hormone)
      compared to the use of vitamin D nutritional supplements (calcifediol) in patients with
      renal transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of patients with iPTH serum concentration &gt;110 pg/mL.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of patients with iPTH serum concentration &gt;110 pg/mL post transplantation and 6 month after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change on iPTH serum concentration</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change on iPTH serum concentration on each treatment group 6 month post transplantation and treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with at least iPTH≥30% of reduction from basal level.</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients that reach at least a 30% iPTH reduction at the end of the study.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with iPTH levels between 70-110 pg/mL at the end of the study.</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patient with presence of calcifications on protocol renal biopsies at 6 months after treatment en each treatment group.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, compared and separate,  of each of the following events: acute rejection, acute rejection confirmed with biopsy and/or subclinic rejection and/or chronic damage.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of alloreactive T memory cells against donor's antigen at 6 months after treatment en each treatment group.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on concentration of bone markers (alkaline phosphatase and osteocalcin) and FGF-23 (Fibroblast growth factor 23) at 6 months after transplantation and treatment on each treatment group.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with acute rejection at 6 months after transplantation and treatment on each treatment group.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with delayed graft function at 6 months after treatment en each treatment group.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with microalbuminuria on months 1, 3 and 6 post transplantation.</measure>
    <time_frame>Months 1, 3 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients on each stage of renal function on months 1, 3 and 6 post transplantation.</measure>
    <time_frame>Months 1, 3 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of blood pressure, speed of pulse wave, calcium-phosphorus metabolic parameters throughout the study and evolution of bone mineral density at 6 post transplantation.</measure>
    <time_frame>6 months.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with hypercalcemia on each treatment group at 6 months post transplantation.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Percentage of patients with hypercalcemia  (defined as serum calcium levels &gt; 10,3 mg/dl) on each treatment group at 6 months post transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of anti-HLA antibodies (PRA) from basal to month 6 post-transplantation.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events or serious adverse events that occurs during the study on each treatment group.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Secondary Hyperparathyroidism Due to Renal Causes</condition>
  <arm_group>
    <arm_group_label>Paricalcitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paricalcitol oral capsules.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcifediol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcifediol oral drops.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol</intervention_name>
    <description>1 capsule/day for 6 months. On Month 1 and Month 3 it can be increased up to 2 capsules/day or decreased down to 1 capsule/48 hours.</description>
    <arm_group_label>Paricalcitol</arm_group_label>
    <other_name>Zemplar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcifediol</intervention_name>
    <description>5 drops/day during 6 months. On Month 1 it can be increased up to 7 drops/day. If this occurs then, on Month 3, it can decreased to 5 drops/day or continue 7 drops/day until end of treatment.</description>
    <arm_group_label>Calcifediol</arm_group_label>
    <other_name>Hidroferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient that have willingly signed and dated the ICD (Informed Consent Document)
             approved by the EC (Ethics Committee) before any study procedure and after they have
             been explained the study,  they have read the ICD and have had the opportunity to
             make questions about it.

          -  Patients of both genders and older than 18 years candidates to an immediately renal
             transplantation from living or deceased donor.

          -  24 hours previous to the transplantation, patient must have a significant grade of
             secondary hyperparathyroidism, defined as iPTH levels between 250 and 600 pg/mL as
             per central laboratory results.

          -  Patients with a preformed antibody panel &lt;20% 24 hours before the transplantation or
             that are considered by the investigator of low immunological risk (PRA determination
             is being done on local laboratory, not central).

          -  Serum calcium (corrected by albumin) &lt; 10 mg/dL 24 hour previous to the
             transplantation as per central laboratory results.

          -  Patients that are to be treated with immunosuppression based on tacrolimus, mofetil
             mycofenolate or mycophenolic acid and with steroids and that are not going to be
             treated with mTOR (mammalian target of rapamycin) inhibitors. Tacrolimus and steroids
             must not be removed on the 6 month post-transplantation.

          -  Patients that are able to take oral capsules on the first week post-transplantation.

        Exclusion Criteria:

          -  Third or subsequent renal transplantation.

          -  Positive cross-match assay or ABO (A-B-0) incompatibility

          -  Patients that have been or are going to be recipients of other organs other than the
             kidney or a double kidney transplantation.

          -  Patients with history of allergic reaction or sensibility to paricalcitol,
             calcifediol or similar study drugs (related with vitamin D).

          -  Patients with chronic gastrointestinal disease, that, based on investigators
             criteria, can cause significant gastrointestinal malabsorption.

          -  Patient with hypo or hyperthyroidism not controlled based on investigators criteria.

          -  Patient with uncontrolled hypertension based on investigators criteria.

          -  Patients that, 48 hours previous to transplantation, have been receiving
             calcimimetics.

          -  Patients with VIH (human immunodeficiency virus)infection of positive serology for
             HBV (hepatitis B virus) and/or HCV (hepatitis C virus)

          -  Patients on treatment with drugs  contraindicated with paricalcitol and calcifediol
             (based on SMPC)

          -  Patients that are participating on other clinical trial with investigational drugs.

          -  Women of childbearing potential (defined as those whose last menstruation was &lt;2
             years ago and that are not surgically sterilized) that are not willing to use correct
             contraception during study treatment.

          -  Patient with other diseases or conditions that based on investigators criteria are
             not suitable for the study.

          -  Treatment will not be started if the Calcium-Phosphorus product (CAxP)is &gt;55 mg2/dL2
             or in case of hyperphosphatemia considered significant as per investigator criteria
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep M Cruzado, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación SENEFRO - Hospital Universitario de Bellvitge - Barcelona.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Josep M Cruzado, Dr</last_name>
    <phone>+34 93 260 76 02</phone>
    <email>jmcruzado@bellvitgehospital.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nieves Collantes</last_name>
    <phone>+34 902 92 92 10</phone>
    <email>senefro.nieves@senefro.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias I Pujol de Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Lauzurica, Dr</last_name>
      <email>rlauzurica.germanstrias@gencat.cat</email>
    </contact>
    <investigator>
      <last_name>Ricardo Lauzurica, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep M Cruzado, Dr</last_name>
      <phone>+34 93 2607602</phone>
      <email>jmcruzado@bellvitgehospital.cat</email>
    </contact>
    <investigator>
      <last_name>Josep M Cruzado, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Carlos Ruiz Sanmillán, Dr</last_name>
      <phone>+34 94 202520</phone>
      <email>ruizjc@humv.es</email>
    </contact>
    <investigator>
      <last_name>Juan Carlos Ruiz Sanmillán, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Canarias</name>
      <address>
        <city>San Cristobal de La Laguna</city>
        <state>Las Palmas de Gran Canaria</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armando Torres Ramírez, Dr</last_name>
      <phone>+34 922 678000</phone>
      <email>atorres@ull.es</email>
    </contact>
    <investigator>
      <last_name>Armando Torres Ramírez, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundació Puigvert-Iuna</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta Del Mar</name>
      <address>
        <city>Cádiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario A Coruña</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domingo Hernández Marrero, Dr</last_name>
      <phone>+34 951 290000</phone>
      <email>Domingohernandez@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Domingo Hernández Marrero, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari I Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>August 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperparathyroidism</keyword>
  <keyword>Hyperparathyroidism Secondary</keyword>
  <keyword>Paricalcitol</keyword>
  <keyword>Calcifediol</keyword>
  <keyword>Parathyroid hormone</keyword>
  <keyword>Renal transplantation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcifediol</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
